Pharmaceutical company touts 'breakthrough' cancer treatment


Patients participating in a trial for a new lung cancer treatment have shown signs of improved health, leading the pharmaceutical company behind the study to hail a major "breakthrough” in the field.

>> Read more trending news

The American company Bristol-Myers Squibb reported Monday that lung cancer patients treated with a combination of its anti-tumor drug Opdivo and its melanoma drug Yervoy showed encouraging results.

According to the company, the treatment fared better than chemotherapy for individuals with "first-line advanced non-small cell lung cancer," known as NSCLC.

>> Related: Just one drink a day can increase your risk of cancer, study warns

"This Phase 3 study shows superior PFS (progression-free survival) with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB (tumor mutation burden)," Dr. Matthew D. Hellmann, study investigator and medical oncologist at Memorial Sloan Kettering Cancer Center, said in a press release.

Dr. Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb, said that his company sees the results as "a breakthrough in cancer research and a meaningful step forward in determining which first-line lung cancer patients may benefit most from the combination of Opdivo and Yervoy."

>> On AJC.com: 7 surprising things that can increase your risk of cancer

"These findings attest to our deep understanding of cancer biology, leading translational medicine capabilities and commitment to developing new approaches for cancer patients," he added.

The treatment trials are currently in their final phase, meaning the next step is to seek approval from the Food and Drug Administration to market the drug combination as a treatment for this specific condition. A panel of experts formed to assess the data recommended that the clinical trial move forward, despite some modifications made during the trial, according to the company.

>> Related: New cancer 'vaccine' completely wipes out tumors in mice -- human trials are on way

Bristol-Myers Squibb has been a pioneer in immunotherapy, according to Reuters. But some analysts are still holding out to see whether or not the treatment will be a success.

"Overall survival is what matters," BMO Capital Markets analyst Alex Arfaei said, explaining that regulators prefer that standard.

"The survival benefit may not be that great," he added, pointing to other new promising treatments.

One analyst called the study "a clear win" for the company, but another cautioned that the report is "positive but unquantified data," according to Bloomberg.

Critics questioned whether the pharmaceutical company’s clinical trial design change may have sullied the results.

>> Related: Long-term aspirin users at lower risk of cancer, study concludes

According to MarketWatch, researchers made changes to the Phase 3 trial, called CheckMate-227, while it was already ongoing.

Bristol-Myers management addressed the concerns Monday in a conference call, stating that it responded to emerging science and only made changes after conversations with the Food and Drug Administration.

Nonetheless, the company is hailing the trials as "a true example" of "innovation."

>> On AJC.com: ‘One-stop’ blood test to detect cancer shows promise, scientists say

Overall survival data from the Opdivo and Yervoy combination trial will be released near the end of 2018 or early in 2019 the company said.

Already, Opdivo is the company's best-selling drug, reporting sales of $4.95 billion globally last year.

"By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers," Bristol-Myers Squibb explained.

>> Related: 72 major genetic risk factors for breast cancer identified in new study

The new trials will likely increase the drug's profitability as they further demonstrate its benefits, the company said. However, Seamus Fernandez, an analyst at Leerink Partners, pointed out that it remains to be seen whether combining Opdivo with Yervoy provides better results than taking the drug alone.

For now, Bristol-Myers Squibb is thanking the patients who participated in the trial leading to the "breakthrough."

"We would like to thank the patients and researchers who participated in these clinical trials — without whom this scientific advance would not be realized," the company said in a statement.


Reader Comments ...


Next Up in Nation & World

Royal Wedding: Meghan Markle, Prince Harry wed (live updates)
Royal Wedding: Meghan Markle, Prince Harry wed (live updates)

Actress Meghan Markle and Britain’s Prince Harry got married Saturday in a highly anticipated, star-studded ceremony in St. George’s Chapel at England’s Windsor Castle.  Update 6:21 a.m. EDT Sunday: The British royal family took to Twitter late Saturday to congratulate Prince Harry and Meghan Markle and thank their guests...
'Royal wedding guest name' quiz could help scammers get your personal data
'Royal wedding guest name' quiz could help scammers get your personal data

A seemingly innocent quiz that has been sweeping social media could help scammers get their hands on your personal data, experts say. "What's your royal wedding guest name?" the meme, which began circulating ahead of Saturday's royal wedding, asks. One version reads as follows: "In honor of the royal wedding, use your 'royal wedding...
2 inmates escape Ohio prison, still at large, deputies say
2 inmates escape Ohio prison, still at large, deputies say

Law enforcement is asking for the public’s help to find two Ohio prisoners who escaped Saturday night from the Community Correctional Center in Turtlecreek Township. Deputies from the Warren County Sheriff’s Office responded around 8:30 p.m. to the area of 5234 State Route 63, the CCC, for a report of two men running through a...
Barber throws man who complained about haircut through window
Barber throws man who complained about haircut through window

A man got more than his hair cut, when an argument with the barber over the style led to the man getting thrown through a glass window, police said.  The 33-year old victim was not satisfied with his haircut Thursday and threatened not to pay, according to the New York Daily News. In response, the barber at Levels Barbershop, in Brooklyn...
Dog dies after being left in hot car
Dog dies after being left in hot car

A man is facing animal cruelty charges after he reportedly left a dog in a hot car.  The dog later died despite efforts to rescue him. Anthony Griffith is charged with animal cruelty after the dog was left in a car at Southeast Georgia Health System in St. Marys.  The dog fell to the pavement when an officer arrived and opened the car door...
More Stories